BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharma Announces Proposed Public Offering of Securities

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsFinancing

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public

Related news

PMVPPMV Pharmaceuticals2026-09-01 03:04 EST

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

ZNTLZentalis2026-08-13 20:01 EST

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

IMTXImmatics2026-08-25 11:00 EST

Immatics Announces $150 Million Underwritten Offering

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

PMVPPMV Pharmaceuticals2026-09-08 12:00 EST

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST

Teva Announces Launch of Offering of Senior Notes

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-09-08 12:00 EST

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMVPPMV Pharmaceuticals2026-09-01 03:04 EST

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:02 EST

PMV Pharma Announces Proposed Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:01 EST

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.46 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States